In today’s recent session, 2.26 million shares of the ImmunityBio Inc (NASDAQ:IBRX) have been traded, and its beta is 0.80. Most recently the company’s share price was $2.91, and it changed around -$0.03 or -0.85% from the last close, which brings the market valuation of the company to $2.13B. IBRX at last check was trading at a discount to its 52-week high of $10.53, offering almost -261.86% off that amount. The share price’s 52-week low was $2.28, which indicates that the recent value has risen by an impressive 21.65% since then. We note from ImmunityBio Inc’s average daily trading volume that its 10-day average is 7.17 million shares, with the 3-month average coming to 7.38 million.
ImmunityBio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended IBRX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. ImmunityBio Inc is expected to report earnings per share of 0 for the current quarter.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX has been showing red trend so far today with a performance of -0.85% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.30 on recent trading dayincreased the stock’s daily price by 11.82%. The company’s shares are currently up 13.87% year-to-date, but still up 17.54% over the last five days. On the other hand, ImmunityBio Inc (NASDAQ:IBRX) is 3.00% up in the 30-day period. We can see from the shorts that 50.01 million shares have been sold at a short interest cover period of 7.44 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 51.5% from its current value. Analyst projections state that IBRX is forecast to be at a low of $6 and a high of $6.
ImmunityBio Inc (IBRX) estimates and forecasts
ImmunityBio Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -49.65 percent over the past six months and at a 7.07% annual growth rate that is well below the industry average of 16.50%. The year-over-year growth rate is expected to be 3,310.93%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 7.81M in revenue for the current quarter. 2 analysts expect ImmunityBio Inc to make 23.09M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 139k and 40k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 5,516.55%. Forecasts for the next quarter put sales growth at 57,618.75%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.17%.
IBRX Dividends
ImmunityBio Inc’s next quarterly earnings report is expected to be released in February.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 73.49% of ImmunityBio Inc shares, and 9.62% of them are in the hands of institutional investors. The stock currently has a share float of 36.28%. ImmunityBio Inc stock is held by 255.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 2.0558% of the shares, which is about 13.83 million shares worth $87.42 million.
BLACKROCK INC., with 1.6978% or 11.42 million shares worth $72.19 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 5.72 shares worth $17.13 million, making up 0.82% of all outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held roughly 4.9 shares worth around $14.67 million, which represents about 0.70% of the total shares outstanding.
